Chat with us, powered by LiveChat

Author name: emma.scrafton

Hi, I'm Emma, and I work within the Marketing team at Lhasa Limited. I have a masters degree in Chemistry.

Supporting the safe use of CDB in skincare products using Derek Nexus

Supporting the safe use of CBD in skincare products using Derek Nexus

Cannabidiol (CBD) is gaining prominence as a sought-after ingredient in skincare and beauty formulations, thanks to its notable anti-inflammatory, antioxidant and anti-bacterial properties. Derived directly from the hemp plant, this compound is increasingly being used as an ingredient in skincare products, particularly for the management of various skin conditions like eczema, dermatitis and psoriasis. Despite […]

Supporting the safe use of CBD in skincare products using Derek Nexus Read More »

Scientist Spotlight: Poster Shortlisted for Top 10 Best Risk Assessment Abstract at Society of Toxicology!

Scientist Spotlight: Poster Shortlisted for Top 10 Best Risk Assessment Abstract at Society of Toxicology!

One of our three Lhasa Limited posters during the recent Society of Toxicology 63rd annual meeting was selected for the top 10 best risk assessment abstract award by the Risk Assessment Speciality Section! Authored by Lhasa scientist, Pooja Tomar, the poster titled “Best practice for conducting expert review of sensitisation data and predictions​” highlights the critical

Scientist Spotlight: Poster Shortlisted for Top 10 Best Risk Assessment Abstract at Society of Toxicology! Read More »

Lhasa Limited publication awards 2023

The ultimate 2024 reading list, as chosen by our members!

Throughout 2023, our dedicated team contributed significantly to various journals through authoring and co-authoring a plethora of publications. Here are the articles, as voted by our members, which stood out above the rest. Organised into 5 compelling categories; Extractables and Leachables, Nitrosamines, Potentially Mutagenic Impurities (PMIs), Data Sharing and Safety Profiling in Drug Discovery, we

The ultimate 2024 reading list, as chosen by our members! Read More »

Copy of Blog images 1080 × 864 px 2

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs

Building on the success of our recent webinar, How to establish acceptable intake (AI) limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs), we’re thrilled to present a follow-up that brings you closer to the insightful discussions that unfolded during the interactive Q&A session. In this blog, we’ve gathered questions posed during the webinar and curated written

Q&A deep dive with Martin Walter: How to establish AI limits for NDSRIs Read More »

Blog images 1080 × 864 px 2

Current status of the Ames test for N-nitrosamines

In our earlier instalments of the Lhasa blog, we have discussed the latest regulatory insights presented by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and Health Canada regarding acceptable intake limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Now, our focus zeroes in on the Enhanced Ames Test (EAT) and its

Current status of the Ames test for N-nitrosamines Read More »

NDSRI 1

What you need to know about the FDA’s new guidance on NDSRIs

The U.S. Food and Drug Administration (FDA) recently took a significant step forward in safeguarding public health by issuing a new guidance titled “Recommended Acceptable Intake Limits for Nitrosamine Drug Substance Related Impurities (NDSRIs) Guidance for Industry.” This important update addresses concerns related to NDSRIs, a group of nitrosamine impurities found in numerous drug products,

What you need to know about the FDA’s new guidance on NDSRIs Read More »

Read across blog 2

The future of dermatological safety: FDA’s new approach to predicting dermal sensitisation

Traditional methods for evaluating the immunotoxic potential of pharmaceuticals typically involve animal testing, which is time-consuming, costly, and raises ethical concerns. In response to these challenges, regulatory agencies, including the Food and Drug Administration (FDA), are actively encouraging the development and acceptance of alternative methods. FDA’s new guidance on dermal sensitisation The FDA has recently

The future of dermatological safety: FDA’s new approach to predicting dermal sensitisation Read More »

Veterinary medicines blog

Harnessing (Q)SAR models to control mutagenic impurities in veterinary medicinal products

Veterinary medicines are commonly used by veterinarians, farmers and pet owners to treat and prevent animal diseases. Like what is already in place for pharmaceutical products within ICH M7, a guideline is also available for veterinary medicinal products to ensure appropriate control of mutagenic impurities. The guideline provides a practical framework that is applicable to

Harnessing (Q)SAR models to control mutagenic impurities in veterinary medicinal products Read More »